Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Business Combination, Contingent Consideration, Liability

Business Combination, Contingent Consideration, Liability at other companies

Viatris logo
ViatrisVTRS
——
Amgen logo
AmgenAMGN
——

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.88B+18.3%
Enterprise value$1.87B+5.8%
P/E20.4×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiability.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's business combination, contingent consideration, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's business combination, contingent consideration, liability?
ANI Pharmaceuticals (ANIP) reported business combination, contingent consideration, liability of $8.6M in Q1 2026.
How has ANI Pharmaceuticals's business combination, contingent consideration, liability changed year-over-year?
ANI Pharmaceuticals's business combination, contingent consideration, liability decreased by 26.5% year-over-year, from $11.7M to $8.6M.
What is the long-term trend for ANI Pharmaceuticals's business combination, contingent consideration, liability?
Over 2 years (2023 to 2025), ANI Pharmaceuticals's business combination, contingent consideration, liability has grown at a -41.2% compound annual growth rate (CAGR), from $24M to $8.3M.